cilgavimab   Click here for help

GtoPdb Ligand ID: 11329

Synonyms: AZD1061 | COV2-2130 | Evusheld® (tixagevimab + cilgavimab)
Compound class: Antibody
Comment: Cilgavimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2 [2]. It was developed by AstraZeneca. This mAb blocks spike binding to ACE2 and prevents infection in animals. It is designed to be a long-acting agent, and in combination with tixagevimab (co-packaged combination= Evusheld®), is proposed as a therapeutic for those people who are likely to respond poorly to SARS-CoV-2 vaccines, or who cannot be vaccinated for any reason, including those who are immunocompromised [1]. Data from the Phase 3 PROVENT trial (NCT04625725) show protection from infection that lasts for at least six months. AstraZeneca have reported that Evusheld® retains neutralising activity against the omicron (B.1.1.529) SARS-CoV-2 variant.
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
11777 cilgavimab
Synonyms Click here for help
AZD1061 | COV2-2130 | Evusheld® (tixagevimab + cilgavimab)
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1106
Other databases
GtoPdb PubChem SID 434321764
Search PubMed clinical trials cilgavimab
Search PubMed titles cilgavimab
Search PubMed titles/abstracts cilgavimab